Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 13Recruiting 3Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 4Hodgkin Disease 3Triple Negative Breast Neoplasms 2Rhabdomyosarcoma 2Recurrence 2Neoplasms 2Advanced Breast Cancer 2Neoplasm Metastasis 1NSCLC 1Metastatic HER2-positive Breast Cancer 1Lung Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2-negative Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Adenocarcinoma 1

Interventions

Cyclophosphamide 13pembrolizumab 8Brentuximab Vedotin 8fludarabine 7Nivolumab 7Whole-Body Irradiation 6Specimen Handling 6Mycophenolic Acid 6Gemcitabine 6Etoposide 6Doxorubicin 6Dacarbazine 6fludarabine phosphate 5Vinblastine 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Dexamethasone 5Stem Cell Transplantation 4Cytarabine 4Vinorelbine 3Tacrolimus 3Magnetic Resonance Spectroscopy 3Cyclosporine 3Carmustine 3Blood Specimen Collection 3thymoglobulin 2polatuzumab vedotin 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Hodgkin Disease × Vinorelbine × Clear all
NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
71 enrolled
Lymphoid

Hodgkin Disease

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
257 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05300282 2026-01-28

FIL_A-BEGEV

Fondazione Italiana Linfomi - ETS

Phase 1/2 Recruiting
122 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡